Download PDF
Horm Metab Res 2003; 35(2): 86-91
DOI: 10.1055/s-2003-39056
Original Clinical
© Georg Thieme Verlag Stuttgart · New York

Clinical, Metabolic and Endocrine Parameters in Response to Metformin in Obese Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind and Placebo-Controlled Trial

K.  H.  Chou 1 , H.  von Eye Corleta 1 , E.  Capp 2, 3 , P.  M.  Spritzer 2, 4
  • 1 Gynecology and Obstetrics Service, Hospital of Santa Casa de Misericórdia de Porto Alegre, RS, Brazil and Post-Graduation Program in Clinical Medicine, Universidade Federal do Rio Grande do Sul
  • 2 Department of Physiology Universidade Federal do Rio Grande do Sul
  • 3 Department of Obstetrics and Gynecology, Universidade Federal do Rio Grande do Sul
  • 4 Gynecological Endocrinology Unit, Division on Endocrinology, Hospital de Clínicas de Porto Alegre, Brazil
Further Information

Publication History

Received 6 May 2002

Accepted after revision 27 November 2002

Publication Date:
07 May 2003 (online)

Also available at
    Permissions and Reprints

Abstract

There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS). The aim of this study was to asses the effect of metformin on clinical, metabolic and hormone parameters in obese women with PCOS. Thirty obese, non-diabetic women with PCOS received 500 mg of metformin or placebo, TID, over 90 days. Assessed parameters included body mass index, waist-to-hip ratio, blood pressure, FSH, LH, total testosterone, SHBG, fasting insulinemia, insulin-to-glucose ratio, total, HDL and LDL cholesterol, triglycerides, and menstrual cycles before and after the use of the drugs. Before treatment, patients did not differ in the two groups. After 90 days of metformin use, PCOS women presented significantly lower levels of total testosterone (p = 0.030) and total cholesterol (p = 0.023) compared to the women that used placebo. The other parameters did not differ between the groups. In conclusion, obese women with PCOS may benefit from the use of metformin through the reduction of hyperandrogenemia, total cholesterol, and possibly by restoration of regular menstrual cycles. Further studies with longer follow-ups are necessary to determine cardiovascular and endometrial metformin benefits and insulin-resistance decrease in women with polycystic ovary syndrome.

Key words

Obesity - Hyperandrogenism - Insulin Resistance - Anovulation - Hyperinsulinemia - Cholesterol - Insulin-Sensitizing Drugs

References

  • 1 Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.  J Clin Endocrinol Metab. 1998;  83 3078-3082
    CrossrefPubMedGoogle Scholar
  • 2 Zawadski J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Evans JR, Hersaltine S, Marriam GR (eds). Polycystic Ovary Syndrome Boston; Blackwell 377-384 1990
    Google Scholar
  • 3 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome.  Diabetes. 1989;  38 1165-74
    CrossrefPubMedGoogle Scholar
  • 4 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
    CrossrefPubMedGoogle Scholar
  • 5 Talbott E, Clerici A, Berga S L, Kuller L, Guzick D, Detre K, Daniels T, Engberg R A. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study.  J Clin Epidemiol. 1998;  51 415-422
    CrossrefPubMedGoogle Scholar
  • 6 Wild R A, Alaupovic P, Parker I J. Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance.  Am J obstet Gynecol. 1992;  166 1191-1197
    PubMedGoogle Scholar
  • 7 Guzick D S, Talbott E, Sutton-Tyrell K, Herzog H C, Kuller L H, Wolfson J r. Carotid atherosclerosis in women with polycystic ovary syndrome; initial results from a case-control study.  Am J Obstet Gynecol. 1996;  174 1224-1232
    PubMedGoogle Scholar
  • 8 Rajkhowa M, Neary R H, Kumpatla P, Game F L, Jones P W, Obhrai M S, Clayton R N. Altered composition of high density lipoproteins in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1997;  82 3389-3394
    CrossrefPubMedGoogle Scholar
  • 9 Velazquez E M, Mendoza S, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.  Metabolism. 1994;  43 647-654
    CrossrefPubMedGoogle Scholar
  • 10 Nestler J E, Jakubowicz D J. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.  N Eng J Med. 1996;  335 617-623
    CrossrefPubMedGoogle Scholar
  • 11 Ünlühizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.  Clin Endocrinol. 1999;  51 231-236
    CrossrefPubMedGoogle Scholar
  • 12 Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.  J Clin Endocrinol Metab. 2000;  85 139-146
    CrossrefPubMedGoogle Scholar
  • 13 Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni G E, Filicori M, Morselli-Labate A M. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2000;  85 2767-2774
    CrossrefPubMedGoogle Scholar
  • 14 Crave J C, Fimbel S, Lejeune H, Cugnardey N, Déchaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.  J Clin Endocrinol Metab. 1995;  80 2057-2062
    CrossrefPubMedGoogle Scholar
  • 15 Açbay Ö, Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome?.  Fertil Steril. 1996;  65 946-949
    PubMedGoogle Scholar
  • 16 Ehrmann D A, Cavaghan M K, Imperial J, Sturis J, Rosenfield R L, Polonsky K S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1997;  82 524-530
    PubMedGoogle Scholar
  • 17 Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women.  J Clin Endocrinol Metab. 1961;  21 1440-1447
    CrossrefPubMedGoogle Scholar
  • 18 World Health Organization .Diet, nutrition and prevention of chronic disease. Report of a WHO Study Group. Technical Report Series 797. Geneva; WHO 203 1990
    Google Scholar
  • 19 World health Organization Study Group .Prevention of Diabetes Mellitus. Geneva; World Health Organization, WHO Technical Report Series 844 100 1994
    Google Scholar
  • 20 Spritzer P M, Billaud L, Thalabard J, Kuttenn F, Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late onset adrenal hyperplasia.  J Clin Endocrinol Metab. 1990;  70 642-645
    PubMedGoogle Scholar
  • 21 Harris M I, Hadden W C, Knowler W. International criteria for the diagnosis of diabetes and impaired glucose tolerance.  Diabetes Care. 1985;  8 562-567
    PubMedGoogle Scholar
  • 22 Spritzer P M, Poy M, Wiltgen D, Mylius L S, Capp E. Leptin concentrations in hirsute women with polycystic ovary sydrome or idiopathic hirsutism: influence on LH and relationship with hormonal, metabolic and anthropometric measurements.  Hum Reprod. 2001;  16 1340-1346
    CrossrefPubMedGoogle Scholar
  • 23 de Fronzo R A, Tobin J D, Adres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance.  Am J Physiol. 1979;  237 E214-E223
    PubMedGoogle Scholar
  • 24 Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.  Eur J Endocrinol. 1998;  138 269-274
    CrossrefPubMedGoogle Scholar
  • 25 Pirwany L R, Yates R WS, Cameron I T, Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.  Hum Reprod. 1999;  14 2963-2968
    CrossrefPubMedGoogle Scholar
  • 26 DeFronzo R A, Barzilai N, Simonson D C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.  J Clin Endocrinol Metab. 1991;  73 1294-1301
    CrossrefPubMedGoogle Scholar
  • 27 Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich J E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.  N Eng J Med. 1995;  333 550-554
    PubMedGoogle Scholar
  • 28 Maturana M A, Spritzer P M. Association between hyperinsulinemia and endogenous androgen levels in peri and postmenopausal women.  Metabolism. 2002;  51 238-243
    CrossrefPubMedGoogle Scholar
  • 29 Haffner S M, Newcomb P A, Marcus P M. Relation of sex hormones and dehydroepiandrosterona sulfate (DHEA-SO4) to cardiovascular risk factor in postmenopausal women.  Am J Epidemiol. 1995;  142 925-934
    PubMedGoogle Scholar
  • 30 Bruun J M, Pedersen S B, Richelsen B. Interleukin-8 production in human adipose tissue. Inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin.  Horm Metab Res. 2000;  32 537-541
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Morin-Papunen L C, Koivunen R M, Ruokonen A, Martikainen H K. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.  Fertil Steril. 1998;  69 691-696
    CrossrefPubMedGoogle Scholar
  • 32 Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.  N Engl J Med. 1998;  338 1876-1880
    PubMedGoogle Scholar
  • 33 de Leo V, La M arca, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.  Fertil Steril. 1999;  72 282-285
    CrossrefPubMedGoogle Scholar

Dra. H. von Eye Corleta

Gynecology and Obstetrics · Hospital of Santa Casa de Misericórdia de Porto Alegre

Rua Ramiro Barcelos · 910 conj. 905 · CEP 90035-001 · Porto Alegre, RS · Brazil ·

Phone: + 55(51)33115699

Fax: + 55(51)33116588

Email: hcorleta@portoweb.com.br

      >